Brexanolone

Sharing is caring!

Brexanolone Brand Name– ZULRESSO

What is Brexanolone

Brexanolone is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator for the treatment of postpartum depression in adults.

Brexanolone is an analog of allopregnanolone, an endogenous steroid hormone metabolite that increases during pregnancy and then declines abruptly after birth. In some women, this decline is thought to trigger depression and anxiety.

Patients, treating healthcare facilities, wholesalers, distributors, and dispensing pharmacies of brexanolone must be enrolled in the Zulresso REMS monitoring program due to the risk of excessive sedation or loss of consciousness.

A healthcare provider must be available on site to continuously monitor the patient, and intervene as necessary, for the duration of the 60-hour intravenous infusion.

Patients must be monitored for hypoxia with continuous pulse oximetry and assessed for excessive sedation every 2 hours during planned, non-sleep periods throughout the infusion duration.

Indications

  • postpartum depression

Side Effects

  1. diarrhea
  2. dizziness
  3. drowsiness
  4. dyspepsia
  5. fatigue
  6. flushing
  7. hypoxia
  8. injection site reaction
  9. loss of consciousness
  10. sinus tachycardia
  11. suicidal ideation
  12. syncope
  13. vertigo
  14. xerostomia

Monitoring Parameters

  • neurologic function
  • pulse oximetry

Contraindications

  • abrupt discontinuation
  • activities requiring coordination and concentration
  • breast-feeding
  • CNS depression
  • coadministration with other CNS depressants
  • driving or operating machinery
  • ethanol ingestion
  • hypoxemia
  • loss of consciousness
  • pregnancy
  • renal failure
  • requires a specialized care setting
  • suicidal ideation

Interactions

There are no drug interactions associated with Brexanolone products.

Sharing is caring!

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856